At J-ALEX IA, Alectinib demonstrated significantly prolonged PFS compared with Crizotinib and was well tolerated with a favorable AE profile. READ ARTICLE
Journal of Clinical Oncology DOI: 10.1200/JCO.2016.34.15_suppl.9008
Authors: Hiroshi Nokihara, Toyoaki Hida, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Koichi Goto, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Hiroshi Kuriki, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura